News from sigma-tau A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 21, 2014, 06:00 ET

VSL#3, Clinically-Studied Probiotic Kept Refrigerated Behind The Pharmacy Counter, Now Showing At Shelf With A Card, A First In The Probiotic Category

 Consumers have gotten used to seeing shelf cards in place of full product packages in certain categories of products, such as cold and flu,...

Jul 11, 2014, 10:07 ET
Sigma-Tau Rare Disease Logo

Einreichung von Sigma-Tau Rare Disease an Europäische Arzneimittel-Agentur (EMA) für die Anwendung von PegylatedL-Asparaginase (Oncaspar®) in der Behandlung von akuter lymphatischer Leukämie

Sigma Tau Pharma Ltd. ("Sigma-Tau Rare Disease") gab heute die Einreichung an die Europäische Arzneimittelagentur für die Nutzung von...

Jul 10, 2014, 18:17 ET
Sigma-Tau Rare Disease Logo

Sigma-Tau Rare Disease presenta una solicitud a la EMA para el uso de Oncaspar®

- Sigma-Tau Rare Disease presenta una solicitud a la Agencia Europea del Medicamento (EMA) para el uso de pegylatedL-asparaginasa...

Jul 10, 2014, 11:55 ET
Sigma-Tau Rare Disease Logo

Sigma-Tau Rare Disease Submits Application to the European Medicines Agency (EMA) for Use of PegylatedL-Asparaginase (Oncaspar®) in the Treatment of Acute Lymphoblastic Leukaemia

Sigma Tau Pharma Ltd. (hereinafter referred to as Sigma-Tau Rare Disease), today announced the submission of an application to the European...

May 28, 2014, 18:38 ET
Logo

Synacthen® (sel hexacétate de tétracosactide) de retour dans les pays européens

Sigma-Tau annonce que Synacthen® (sel hexacétate de tétracosactide) est aujourd'hui disponible dans la plupart des pays...

May 28, 2014, 15:19 ET
Logo

Synacthen ®(tetracosactide hexa-acetate salt) back in European Countries

Sigma-Tau announces that Synacthen ® (tetracosactide hexa-acetate salt) is now available again in most of the European...

May 15, 2013, 07:36 ET

Sigma-Tau Receives Innovation Award From The National Organization for Rare Disorders for Its Advancements in Rare Diseases

 Sigma-Tau Pharmaceuticals, Inc. announced today that the Company was recognized last evening as a rare disease pioneer at the 30th anniversary...

Mar 07, 2013, 15:27 ET

L'Eurartesim® (dihydroartémisinine-pipéraquine) est enregistré dans le premier pays africain

Le Ghana approuve un nouvel antipaludique co-développé par MMV Le Ghana est devenu le premier pays africain à approuver...

Mar 07, 2013, 13:01 ET

Eurartesim® (Dihydroartemisinin-Piperaquine) im ersten afrikanischen Land registriert

Ghana erteilt Zulassung für erstes neues in Zusammenarbeit mit MMV entwickeltes Medikament gegen Malaria Ghana hat als erstes afrikanisches...

Mar 07, 2013, 13:00 ET

Primo paese in Africa registra Eurartesim® (dihydroartemisinin-piperaquine) Ghana approva il nuovo anti-malarico sviluppato insieme a MMV

Il Ghana è il primo paese ad approvare Eurartesim®, una terapia combinata in dose fissa composta da diidroartemisinina e piperachina, a...

Nov 28, 2012, 04:19 ET

Antimalariamedikament von Sigma-tau erhielt vom Medicines for Malaria Venture die Auszeichnung "Projekt des Jahres 2011"

Das Projektteam für Eurartesim® (Dihydroartemisinin-Piperaquin/DHA-PQP), die von erste neue von Sigma-Tau entwickelte...

Nov 28, 2012, 00:45 ET

L'antipaludéen de Sigma-tau se voit décerner le prix du « Projet de l'année » 2011 par Medicines for Malaria Venture

L'équipe du projet de l'Eurartesim®, dihydroartémisinine-pipéraquine (DHA-PQP), première nouvelle entité chimique...

Nov 27, 2012, 14:34 ET

Sigma-tau's Antimalarial Awarded "Project of the Year" 2011 by Medicines for Malaria Venture

The project team for Eurartesim®, dihydroartemisinin-piperaquine (DHA-PQP), the first novel chemical entity developed by Sigma-Tau was...

Nov 27, 2012, 14:19 ET

Il farmaco antimalaria di Sigma-tau riceve il premio "progetto dell' anno" 2011 da Medicines for Malaria Venture

Lo staff responsabile per lo sviluppo di  Eurartesim®, diidroartemisinina/piperachina, il farmaco antimalaria frutto della ricerca...

Jul 25, 2012, 04:02 ET

sigma tau group gestionará directamente la distribución de Oncaspar® desde el 1 de agosto

- Desde el 1 de agosto de 2012, sigma tau group gestionará de forma directa la distribución de Oncaspar®, un fármaco para el...

Jul 25, 2012, 03:00 ET

Il Gruppo sigma-tau dal 1 agosto 2012 rileva la distribuzione di Oncaspar®, farmaco per il trattamento delle leucemie, in Europa, Asia e Australia

Oncaspar, indicato per la cura della Leucemia linfoblastica acuta, è uno degli "orphan drugs" che il gruppo sigma-tau ha acquisito dalla...

Jul 25, 2012, 03:00 ET

Sigma-Tau Gruppe übernimmt ab 1. August 2012 den direkten Vertrieb von Oncaspar®, einem Medikament zur Behandlung von Leukämie, in Europa, Asien und Australien

Oncaspar, ein Medikament zur Behandlung von akuter lymphatischer Leukämie, ist eines der "Arzneimittel für seltene Leiden", welche die...

Jul 13, 2012, 14:16 ET

Richtigstellung der Pressemitteilung: "Sigma-Tau-Gruppe startet Markteinführung von neuem Anti-Malaria-Medikament, Eurartesim® (Dihydroartemisinin-Piperaquin)"

Die in der am 5 Juli 2012 veröffentlichten Pressemitteilung enthaltene Aussage, dass Eurartesim® (Dihydroartemisinin-Piperaquin:...

Jul 06, 2012, 06:39 ET

Sigma-Tau Group begint uitrol van nieuw anti-malariamedicijn, Eurartesim® (dihydroartemisinine-piperaquine)

Eurartesim® (dihydroartemisinine piperaquine: DHA-PQP), de eerste artemisinine-combinatietherapie (ACT) die is goedgekeurd door het Europees...